Union Minister of Health and Family Welfare, Shri Jagat Prakash Nadda, on Friday reviewed the progress and key initiatives of the Indian Pharmacopoeia Commission (IPC), reaffirming its critical role in strengthening India’s pharmaceutical standards and pharmacovigilance framework. The review underscored the Government’s vision of Atmanirbhar Bharat and Viksit Bharat, with a strong emphasis on scientific excellence, self-reliance, and robust healthcare regulation.
Strengthening Pharmacopoeial Standards and Public Health
During the review meeting, held in the presence of Ms. Nivedita Shukla Verma, Secretary, Department of Chemicals and Petro-Chemicals (DoCP) and holding additional charge as Secretary, Ministry of Health and Family Welfare (MoHFW), Shri Nadda commended IPC’s sustained efforts in ensuring the quality, safety, and efficacy of medicines. He noted that the Indian Pharmacopoeia continues to serve as a vital scientific and regulatory reference, maintaining uniform standards of medicines across the country and safeguarding public health.
Indian Pharmacopoeia Gains Global Recognition
Highlighting India’s growing stature in global healthcare regulation, Shri Nadda stated that the Indian Pharmacopoeia is now recognised in 19 countries, reflecting increasing international confidence in India’s regulatory and scientific capabilities. He observed that this recognition further strengthens India’s position as the “Pharmacy of the World” and reinforces the global credibility of Indian pharmacopoeial standards.
Launch of Indian Pharmacopoeia 2026 Announced
The Union Health Minister also announced that the 10th edition of the Indian Pharmacopoeia 2026 is scheduled to be launched in the first week of January 2026. The upcoming edition is expected to further enhance India’s regulatory framework by incorporating updated scientific standards aligned with global best practices.
Focus on Pharmacovigilance and Patient Safety
Shri Nadda emphasized IPC’s pivotal role in implementing the Pharmacovigilance Programme of India (PvPI), which monitors adverse drug reactions to ensure patient safety. He appreciated IPC’s efforts to strengthen reporting mechanisms and build capacity among healthcare professionals, thereby improving drug safety surveillance across the country.
Driving Atmanirbhar Bharat and Global Harmonisation
The Minister lauded IPC’s contribution to Atmanirbhar Bharat by strengthening indigenous scientific expertise and regulatory standards while supporting global public health objectives. He encouraged IPC to continue focusing on innovation, digitalisation, and global harmonisation of standards, in line with the broader vision of Viksit Bharat, to ensure universal access to safe and quality medicines.
IPC Reaffirms Commitment to National and Global Health
Presenting details of IPC’s ongoing activities, Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC, reaffirmed the Commission’s commitment to further strengthening pharmacopoeial and pharmacovigilance standards. He also highlighted IPC’s efforts to enhance international collaboration and contribute meaningfully to national and global health goals.
Conclusion
The review meeting reaffirmed the Indian Pharmacopoeia Commission’s central role in India’s healthcare and pharmaceutical ecosystem. With growing international recognition, strengthened pharmacovigilance systems, and the forthcoming launch of the Indian Pharmacopoeia 2026, IPC continues to advance India’s journey towards self-reliance, global leadership in pharmaceuticals, and a resilient public health framework.
For more real-time updates, visit Channel 6 Network.
Source: PIB
